Total amount raised
$57.6 Millions
Latest funding date
05/01/2022
Location
Curebase has successfully raised funds through multiple rounds, with the latest being a Series B round closed on May 5, 2022. The company has garnered the support of 16 investors, including notable names like Xfund and Gilead Sciences.
Keep reading to explore the intricacies of Curebase's fundraising journey and the investors backing this innovative platform.
What Is Curebase?
Curebase, founded in 2017 by Tom Lemberg, is a San Francisco-based company specializing in decentralized clinical research software solutions. The company operates in the Clinical Trials, Health Care, and Software industries.
With an employee count ranging from 51 to 100, Curebase aims to revolutionize clinical trials through its AI-native platform. Their software solutions, including ePRO/eCOA, eConsent, and EDC, are designed to expedite study launches, enhance data quality, and improve patient engagement.
How Much Funding Has Curebase Raised?
- Seed Round
- Amount Raised: $120K
- Date: August 2018
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To kickstart the development of Curebase's initial software solutions.
- Seed Round
- Amount Raised: $2.5M
- Date: October 2018
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the team and further develop the platform's capabilities.
- Venture Round
- Amount Raised: Not publicly disclosed
- Date: January 2019
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support early-stage growth and product development.
- Venture Round
- Amount Raised: Not publicly disclosed
- Date: April 2020
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To enhance the platform's features and expand market reach.
- Series A
- Amount Raised: $15M
- Date: May 2021
- Lead Investors: Notable Capital
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To scale operations and improve the platform's technological infrastructure.
- Series B
- Amount Raised: $40M
- Date: May 2022
- Lead Investors: Industry Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the end-to-end clinical trial execution model and enhance virtual and hybrid site capabilities.
Total Amount Raised: $57.62M. Current Valuation: Not publicly disclosed.
Key Investors
- Industry Ventures
- Details: Industry Ventures is a leading investment firm that focuses on venture capital and growth equity investments. They have a history of supporting technology companies that are transforming massive, inefficient industries.
- Investment Focus Areas: Technology, Venture Capital, Growth Equity
- Notable Investments: Twitter, Uber
- Gilead Sciences
- Details: Gilead Sciences is a global biopharmaceutical company known for its innovative medicines. They have made a strategic investment in Curebase to deepen their partnership in decentralized and hybrid clinical trials.
- Investment Focus Areas: Biopharmaceuticals, Healthcare, Clinical Trials
- Notable Investments: Not publicly disclosed
- GGV Capital
- Details: GGV Capital is a venture capital firm that invests in technology companies across various stages. They have been an existing investor in Curebase, having led the Series A funding round.
- Investment Focus Areas: Technology, Early-Stage Companies, Growth Equity
- Notable Investments: Alibaba, Slack
- Xfund
- Details: Xfund is an early-stage venture capital firm that focuses on investing in companies with transformative potential. They have been an existing investor in Curebase.
- Investment Focus Areas: Early-Stage Technology, Innovation, Startups
- Notable Investments: 23andMe, Kensho
- Gaingels
- Details: Gaingels is an investment syndicate that focuses on supporting startups with diverse and inclusive teams. They participated in the Series B funding round for Curebase.
- Investment Focus Areas: Diversity, Inclusion, Startups
- Notable Investments: Carta, MasterClass
What's Next for Curebase?
As Curebase continues to ride the wave of decentralized clinical trials, the company is poised to capitalize on the growing demand for more flexible and patient-centric trial models. With a $40 million investment, Curebase is well-positioned to expand its digital infrastructure, making clinical trials more accessible and efficient. This opportunity is vast, with the potential to significantly reduce costs and increase patient participation, especially as the market for decentralized clinical trials rapidly expands.
Future fundraising opportunities seem promising, given the increasing interest in digital health solutions. Curebase could attract additional investments from venture capital firms, private equity, or strategic partnerships with larger healthcare organizations. However, the company will need to navigate regulatory hurdles and ensure data security and patient privacy, which are critical in a digital environment. Competition from other companies in the digital health and clinical trial space could also pose challenges, but Curebase's innovative approach and strong financial backing provide a solid foundation for future growth.
Use Clay to Get Funding Data
Sales professionals, leverage Clay’s platform to access comprehensive fundraising data on companies like Curebase and gather other critical business insights. Sign up for free to start transforming your sales strategy today.
